Results Summary
PCORI funded the development of PCORnet®, the National Patient-Centered Clinical Research Network, to make it easier and more efficient to conduct research. PCORnet is made up of Partner Networks that harness the power of large amounts of health data and patient partnerships.
Patient-Powered Research Networks (PPRNs) are networks operated and governed by patients, families, caregivers, and community members in close collaboration with clinical researchers, with the goal of shaping and conducting research to better serve their communities and improve their health outcomes. Several PPRNs, including American BRCA Outcomes and Utilization of Testing (ABOUT), participated as Partner Networks in PCORnet.
PCORI funded ABOUT’s participation in PCORnet from 2015 to 2019. This report outlines the ABOUT network’s achievements in building its research infrastructure capacity to
- Create ways to involve patients, families, and caregivers in decision making about the network
- Create a way to collect and share data reported by patients for research
- Involve patients, caregivers, families, and communities in the research process, including recruiting people to participate in research studies
- Lead or join in research studies that focus on the community’s priorities
Network at a glance
ABOUT is a PPRN that includes people affected by hereditary breast, ovarian, and related cancers. Hereditary cancers are caused by a mutation, or a change in a gene, that is present at birth. Mutations in BRCA genes can cause breast, ovarian, and related cancers such as pancreatic and prostate cancer and melanoma.
ABOUT is led by the University of South Florida and Facing Our Risk of Cancer Empowered, or FORCE, an advocacy group for individuals and families affected by hereditary breast, ovarian, and related cancers. To help conduct research, the network gathered information from advocacy groups, health insurers, and cancer treatment centers about people diagnosed with these cancers, people with a family history of these cancers, and people with the genetic mutations that cause these cancers. People also provided information themselves through ABOUT’s secure website. The network includes 12,981 individuals affected by hereditary breast, ovarian, and related cancers.
| Title | American BRCA Outcomes and Utilization of Testing (ABOUT) Network |
| Network design | Patient-Powered Research Network (PPRN) |
| Lead partners | University of South Florida Facing Our Risk of Cancer Empowered (FORCE) |
| Other partners | Ovarian Cancer Research Alliance Sharsheret Young Survival Coalition |
| Participants | 12,981 |
| Area(s) of focus | Hereditary breast, ovarian, pancreatic, and prostate cancers, and melanoma |
How does the network operate?
The Executive and Steering Committees lead the network. Patients make up the majority of the Executive Committee, which also includes researchers and key staff from the University of South Florida and FORCE. The Steering Committee is made up of the Executive Committee as well as patients who received special training from FORCE and representatives from each advocacy partner. Two work groups include patients, researchers, doctors, and patient advocates. These work groups help shape and conduct research, determine the best ways to communicate with network participants, and encourage patient participation.
The goal of ABOUT research is to help people with hereditary cancers or an inherited mutation make informed medical decisions to improve their health and well-being. The network developed several tools to increase patient involvement in all stages of research. The primary tool was the GAP (Generate-Assess-Prioritize) 360 process. This process began when people affected by hereditary breast, ovarian, and related cancers generated medical research questions and submitted them through a portal on the network website, an email to a member of the Executive Committee, or a volunteer advocate. Then the Steering and Executive Committees, with feedback from the work groups,
- Assessed and prioritized the research questions
- Submitted research proposals
- Designed and performed studies and analyzed information
- Published research in formats for both the public and professionals
Other ways to increase patient involvement included a search tool that connected patients with research studies enrolling people affected by hereditary cancers and a process that matched trained volunteer research advocates with researchers seeking patient input.
How did the network involve patients and other partners?
Patients hold a majority of positions in the network. Cancer survivors, people who have a gene mutation, and representatives from patient organizations served on the Steering Committee. They also participated on committees that reviewed research ideas, planned and carried out research, and communicated with members of the network.
ABOUT worked with FORCE to develop a course that prepared patients to be involved in the network. Online and in-person sessions covered
- Breast and ovarian cancer
- Genetics
- Statistics
- Research study design
- Patient-centered research
- Medical ethics
- Government regulations for research
Who is in the network?
| Population (as of 03/31/19) |
|---|
Race/ethnicity
Sex
Age
|
The ABOUT network had 12,981 participants as of March 31, 2019. Information about patients for use in research studies came from patients themselves, health insurance companies, cancer treatment centers, patient advocacy groups, and genetic testing. Patients gave their consent before this information was provided.
While a Partner Network in PCORnet, the ABOUT network participated in 13 research studies.
How does the network support future research?
ABOUT is working with other PCORnet networks to identify opportunities for research on hereditary breast, ovarian, and related cancers.
Glossary
Patient-Powered Research Networks (PPRN): PPRNs are operated and governed by patient groups and their partners and are focused on particular conditions or populations.
PCORnet: PCORnet is a network of networks that brings together patients, clinicians, researchers, and healthcare systems to share information and participate in research.
View Phase I Award
Professional Abstract
Overview
PCORI funded the development of PCORnet®, the National Patient-Centered Clinical Research Network, to make it easier and more efficient to conduct research. PCORnet is made up of Partner Networks that harness the power of large amounts of health data and patient partnerships.
Patient-Powered Research Networks (PPRNs) are networks operated and governed by patients, families, caregivers, and community members in close collaboration with clinical researchers, with the goal of shaping and conducting research to better serve their communities and improve their health outcomes. Several PPRNs, including American BRCA Outcomes and Utilization of Testing (ABOUT), participated as Partner Networks in PCORnet.
PCORI funded the ABOUT network’s participation in PCORnet from 2015 to 2019. This report outlines ABOUT’s achievements toward the PPRN goals of developing and optimizing research and engagement infrastructure capacity to
- Establish a governance structure that fully engages patients and other stakeholders for the purposes of contributing to research
- Create a data infrastructure conducive to the ongoing collection of patient-reported data
- Meaningfully engage patients, caregivers, families, and community members in the research process, including identifying and recruiting participants for clinical trials and other research studies
- Lead or partner in the conduct of comparative effectiveness studies responsive to the research priorities of the communities
Network Infrastructure
ABOUT is a PPRN comprising individuals affected by hereditary breast, ovarian, and related cancers. This group includes cancer survivors, individuals with a known mutation who have not been diagnosed with cancer, and individuals with a family history of cancer but no known mutation. Hereditary breast, ovarian, and related cancers, which include prostate and pancreatic cancer and melanoma, are primarily associated with mutations in the BRCA1 and BRCA2 genes.
Led by the University of South Florida and the patient advocacy group Facing Our Risk of Cancer Empowered (FORCE), ABOUT partners include other advocacy organizations, cancer centers, and health insurers. ABOUT aggregates data on people affected by hereditary cancers and maintains a secure web-based patient registry. Currently, the network includes 12,981 individuals.
| Title | American BRCA Outcomes and Utilization of Testing (ABOUT) Network |
| Network design | Patient-Powered Research Network (PPRN) |
| Lead partners | University of South Florida Facing Our Risk of Cancer Empowered (FORCE) |
| Other partners | Ovarian Cancer Research Alliance Sharsheret Young Survival Coalition |
| Participants | 12,981 |
| Area(s) of focus | Hereditary breast, ovarian, pancreatic, and prostate cancers, and melanoma |
Network Governance and Operations
The Executive and Steering Committees manage ABOUT network governance. The Executive Committee includes the primary and co-primary investigators and key staff from the University of South Florida and FORCE. The Steering Committee is made up of the Executive Committee, patients who completed FORCE volunteer training, and representatives from each patient advocacy partner. Two work groups include patients, researchers, clinicians, and advocates. These work groups help shape and conduct research, determine network communication practices, and encourage patient engagement.
The goal of ABOUT research is to help people with hereditary cancers or an inherited mutation make informed medical decisions to improve their health and well-being. The network developed several tools to increase patient engagement across all stages of the research cycle. The primary tool was the GAP (Generate-Assess-Prioritize) 360 process. This process began when people affected by hereditary breast, ovarian, and related cancers generated medical research questions and submitted them through a portal on the network website, an email to a member of the Executive Committee, or a volunteer advocate. Then the Steering and Executive Committees, with feedback from the work groups,
- Assessed and prioritized the research questions
- Submitted research proposals
- Designed and performed clinical studies and analyzed data
- Published research in formats for both professional and lay audiences
Other methods to increase patient engagement included a search tool that connected patients with research studies enrolling people affected by hereditary cancers and a process that matched trained volunteer research advocates with researchers seeking patient input.
Stakeholder Engagement
Patients hold a majority of positions in the network. They were prepared for network participation through a program developed and conducted by FORCE. The program included webinars and live meetings and covered topics such as breast and ovarian cancer, genetics, statistics, clinical trial design, comparative effectiveness research, medical ethics, and governmental regulatory processes for research. After completing the program, patients were designated as research advocates and eligible to serve on work groups. After one year in a work group, they could be nominated to the Steering Committee.
Demographics and Research Capacity
The ABOUT network registered 12,981 participants as of March 31, 2019. The network includes cohorts from two studies that were collaborations between ABOUT and health insurers. Patients had a BRCA genetic test and a personal or family history of breast, ovarian, or related cancers or a known BRCA mutation. Data included health claims data, patient-reported data, and genetic testing results. Additionally, the ABOUT public cohort includes patient-reported data, and, in some cases, genetic testing results submitted through the network portal.
| Population Demographics (as of 03/31/19) |
|---|
Race/ethnicity
Sex
Age
|
While a Partner Network in PCORnet, the ABOUT network participated in 13 studies.
Future Opportunities
ABOUT is continuing to partner with other PCORnet networks and hereditary cancer researchers to identify opportunities for collaboration and provide tools to increase patient engagement in research on hereditary breast, ovarian, pancreatic, and prostate cancer, and melanoma.